The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase
- 1 May 2001
- journal article
- Published by Springer Nature in Inflammopharmacology
- Vol. 9 (1-2) , 113-124
- https://doi.org/10.1163/156856001300248380
Abstract
Since the discovery of aspirin about one century ago, many non-steroidal anti-inflammatory drugs (NSAIDs) have been used for the treatment of inflammatoryKeywords
This publication has 3 references indexed in Scilit:
- The Effects of ML 3000 on Antigen-induced Responses in SheepPulmonary Pharmacology & Therapeutics, 1997
- ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injuryEuropean Journal of Pharmacology, 1994
- Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damageInflammation Research, 1993